Abstract
BackgroundIndividuals and/or caregivers of individuals affected by spinal muscular atrophy (SMA) completed the 2019 Cure SMA Community Update Survey, online, assessing health-related quality of life (HRQoL), loss of work productivity, and fatigue using the Health Utilities Index Questionnaire (HUI), the Work Productivity and Activity Impairment Questionnaire (WPAI), and the Patient Reported Outcomes Measurement Information System Fatigue Short Form (PROMIS Fatigue SF), respectively. The purpose was to collect baseline quality of life results among individuals affected by SMA using the above Patient Reported Outcome Measures (PROMs).ResultsOf 666 surveys completed between March and May 2019, 478 were included in this analysis, accounting for duplicates, missing data, or deaths. The breakdown across SMA type I, II and III was 25, 47 and 28%, respectively. Responses were characterized by current functional status/milestone, with subsets for “permanent ventilation,” “non-sitters,” “sitters,” “walk with support,” and “walk alone.” WPAI and HUI respondents included affected adults and caregivers. The PROMIS Fatigue SF was completed by the primary caregiver of affected children.Overall, those affected by a less severe form of SMA and with a higher functional status reported higher HRQoL and lower work productivity and activity impairment. All affected individuals reported higher fatigue levels than the general population.ConclusionsThis study offers useful insights into the burden of SMA among affected individuals and their caregivers. The results provide a baseline picture of the patient and caregiver experience with SMA in a post-treatment era from which to measure year-over-year changes in quality of life scores from new therapies and improved care. The WPAI demonstrates the significant impact of work productivity among SMA populations. Aspects of the HUI seem more appropriate to certain SMA sub-populations than others. Measures from the PROMIS Fatigue SF appear to under-represent the burden of fatigue often reported by SMA individuals and caregivers; this may, perhaps be due to a lack of sensitivity in the questions associated with fatigue in the SMA affected population, when compared with other studies on this topic. Overall, these results suggest the need for SMA-specific quality of life outcome measures to fully capture clinically meaningful change in the SMA population.
Highlights
Individuals and/or caregivers of individuals affected by spinal muscular atrophy (SMA) completed the 2019 Cure SMA Community Update Survey, online, assessing health-related quality of life (HRQoL), loss of work productivity, and fatigue using the Health Utilities Index Questionnaire (HUI), the Work Productivity and Activity Impairment Questionnaire (WPAI), and the Patient Reported Outcomes Measurement Information System Fatigue Short Form (PROMIS Fatigue SF), respectively
Spinal muscular atrophy (SMA) is a genetic neuromuscular disease characterized by progressive muscle atrophy and weakness that historically often led to paralysis and premature death [1]
Thirty-four duplicate surveys completed for the same affected individual (i.e.: both parents submitted surveys), 63 surveys missing functional status information, 20 surveys relating to deceased individuals, 55 surveys missing diagnosis date and 16 surveys with SMA type other than I, II, or III were excluded from the final dataset
Summary
Individuals and/or caregivers of individuals affected by spinal muscular atrophy (SMA) completed the 2019 Cure SMA Community Update Survey, online, assessing health-related quality of life (HRQoL), loss of work productivity, and fatigue using the Health Utilities Index Questionnaire (HUI), the Work Productivity and Activity Impairment Questionnaire (WPAI), and the Patient Reported Outcomes Measurement Information System Fatigue Short Form (PROMIS Fatigue SF), respectively. Type I SMA (Werdnig Hoffman Disease) presents with severe generalized weakness, hypotonia, tongue fasciculations, and impaired respiratory function, difficulty feeding and swallowing, among other symptoms appearing within the first 6 months of life. More than half of children with type I SMA did not survive to age two [3]. Type II SMA (Kugelberg Welander disease) usually presents between the ages of 6 and 18 months, with affected children being able to sit independently but unable to walk without assistance, with most experiencing respiratory difficulties and progressive scoliosis, and some developing eventual problems with chewing and swallowing. Patients with juvenile SMA (type III) can walk at some point and have a normal life expectancy, they develop muscle weakness over time and often eventually lose ambulation. Patients’ symptoms first appear in adulthood (type IV) [6,7,8]
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have